CJC-1295 DAC vs Ipamorelin: How These Two Peptides Differ

CJC-1295 DAC and ipamorelin are two different peptides that both stimulate growth hormone release, but they act on different receptors and stay active in the body for very different lengths of time. CJC-1295 DAC is a long-acting growth hormone-releasing hormone (GHRH) analog that remains active for days, while ipamorelin is a short-acting ghrelin receptor agonist that clears within hours. Most people comparing them are really choosing between a long, steady GH signal and a short, targeted pulse.

What CJC-1295 DAC Does

CJC-1295 is a modified form of GRF(1-29), the active fragment of natural GHRH. The letters "DAC" stand for Drug Affinity Complex, a chemical addition that lets the peptide bind to albumin in the bloodstream.

That albumin binding is what makes CJC-1295 DAC long-acting. Because the carrier protein slows breakdown, the peptide keeps stimulating the pituitary gland for days after a single injection.

• Receptor: GHRH receptor on pituitary cells
• Half-life: roughly 6 to 8 days
• Typical research dosing: once or twice weekly
• Main effect: raises baseline GH and IGF-1 levels

CJC-1295 DAC is not FDA-approved for human use in the United States. It is sold as a research chemical, and the early human studies of the compound were small.

What Ipamorelin Does

Ipamorelin is a five-amino-acid peptide that mimics ghrelin, the hormone that drives hunger and growth hormone release. It binds the ghrelin receptor, also called GHS-R1a, in the pituitary and hypothalamus.

Its reputation comes from selectivity. Unlike older ghrelin mimetics such as GHRP-6, ipamorelin produces a clean GH pulse with little to no measurable rise in cortisol, prolactin, or appetite in the published research.

• Receptor: ghrelin receptor (GHS-R1a)
• Half-life: roughly 2 hours
• Typical research dosing: two to three times daily
• Main effect: produces sharp, pulsatile GH release

Ipamorelin is not FDA-approved for human use in the United States either. It is likewise sold as a research compound rather than a prescription drug.

CJC-1295 DAC vs Ipamorelin at a Glance

Feature	CJC-1295 DAC	Ipamorelin
Peptide class	GHRH analog	Ghrelin receptor agonist
Receptor target	GHRH receptor	GHS-R1a
Half-life	About 6 to 8 days	About 2 hours
GH pattern	Long, sustained elevation	Short, pulsatile spike
IGF-1 impact	Strong and cumulative	Moderate and transient
Dosing frequency	One or two times weekly	Two or three times daily
Cortisol and prolactin	Minimal change reported	Minimal change reported
FDA approved for human use	No	No

The table captures the core trade-off. CJC-1295 DAC creates a small number of very long GH elevations, while ipamorelin creates frequent short pulses that look closer to the body's natural rhythm.

CJC-1295 DAC vs No DAC: Why the Half-Life Matters

Any comparison of cjc-1295 dac vs no dac comes down to one design decision: whether the peptide carries the Drug Affinity Complex.

Without DAC, CJC-1295 is usually called mod GRF 1-29, and its half-life is measured in minutes rather than days. That version has to be dosed several times daily to be useful.

With DAC, a single injection keeps GH and IGF-1 elevated around the clock. Continuous IGF-1 elevation is the central theoretical safety concern, because chronically high IGF-1 is associated with fluid retention, joint discomfort, insulin resistance, and tissue growth. Short-acting versions let hormone levels fall back to baseline between doses.

This is why many researchers searching for cjc-1295 no dac vs ipamorelin are really comparing two short-acting options instead of one long-acting and one short-acting peptide.

Why CJC-1295 and Ipamorelin Are Usually Stacked

CJC-1295 and ipamorelin hit different receptors, so they function as complements rather than competitors. GHRH analogs amplify the pituitary's response to ghrelin signals, and ghrelin agonists amplify the response to GHRH.

In research models, combining the two produces a larger GH pulse than either peptide alone. That synergy is the main reason the pairing shows up so often in discussions of cjc-1295 ipamorelin vs cjc-1295 dac.

The same logic explains why people also look into sermorelin vs cjc-1295 no dac ipamorelin and cjc-1295 ipamorelin vs tesamorelin. Each alternative changes either the duration of the GHRH signal or the strength of the GH pulse.

Dosing and Protocol Considerations

Every number below comes from research literature and vendor labeling, not from approved prescribing information. There is no FDA-approved dose of either peptide for humans.

1. CJC-1295 DAC alone: commonly described as 1 to 2 mg per week, split into one or two injections.
2. Ipamorelin alone: commonly described as 100 to 300 mcg, two or three times daily, often timed around sleep or training.
3. Stacked: a frequent research design pairs 100 mcg ipamorelin with 100 mcg CJC-1295 no DAC two or three times daily, or with CJC-1295 DAC once weekly.

Timing matters as much as dose. Natural GH release peaks during deep sleep, so many protocols place an injection before bed, while others split doses to capture the post-exercise window.

Safety, Side Effects, and Legal Status

Neither peptide is approved by the FDA for human use, and neither is legally available as a prescription drug in the United States. Products sold online are labeled "for research use only" and are not held to pharmaceutical quality standards.

Reported side effects in research and anecdotal accounts include injection-site irritation, headaches, water retention, joint pain, and fatigue. Because CJC-1295 DAC keeps IGF-1 elevated for days, it creates a longer exposure window than ipamorelin.

People with a history of cancer, diabetes, or pituitary disease are generally advised to avoid growth hormone-related compounds. Anyone considering these substances should speak with a licensed healthcare professional first.

The Short Answer

CJC-1295 DAC is the endurance option and ipamorelin is the precision option. If the goal is a sustained GH and IGF-1 signal with infrequent injections, CJC-1295 DAC fits that description. If the goal is a clean, natural-looking pulse with selective GH release, ipamorelin fits that description.

Because they work through separate receptors, the choice is often "both" rather than "either." Neither compound is approved for human use, and both should be treated as experimental rather than therapeutic.

COMMON QUESTIONS

Frequently Asked Questions

Is CJC-1295 DAC stronger than ipamorelin?

They are not directly comparable because they act on different receptors. CJC-1295 DAC keeps growth hormone and IGF-1 elevated for days at a time, while ipamorelin produces short pulses that clear within hours. Which one produces a larger total effect depends on dose and frequency, not on one peptide being inherently stronger.

Can you stack CJC-1295 DAC with ipamorelin?

Yes, the two are frequently combined in research settings because they hit different receptors and can amplify each other's signal. A common design pairs ipamorelin with either CJC-1295 DAC or the shorter-acting no-DAC version. This is not an FDA-approved use, and no approved human dosing exists.

How long does CJC-1295 DAC stay in your system?

CJC-1295 DAC has a half-life of roughly 6 to 8 days because its Drug Affinity Complex binds to albumin in the blood. Full clearance takes considerably longer than that. Ipamorelin, by contrast, has a half-life of about 2 hours and clears the same day.